Registry · SNY
Does Sanofi S.A. support Israel?
Yes — Sanofi S.A. has documented support for Israel on record. Every claim below links to its source.
Filed under: Pharma & healthcare companies · Companies that support Israel
Background
Sanofi's Israel footprint is commercial: an in-country subsidiary and, most notably, active dealmaking with Israeli biotech — a $125M-upfront global license from Biond Biologics (2021) and a repeatedly expanded AI R&D partnership with Tel Aviv's CytoReason (2021, 2023, 2026). No corporate charitable donations to Israeli or pro-Israel causes were identified, and no evidence of a Sanofi acquisition of an Israeli company was found (the Biond deal is a license, not an acquisition). Sanofi's U.S. employee political action committee was noted but not found disbursing to pro-Israel committees.
Times of Israel (Biond/Sanofi) Times of Israel (Sanofi/CytoReason)
Timeline of documented support
Documented support
| Type | Date | Amount | Recipient | Sources |
|---|---|---|---|---|
| Partnership | 2021-01-12 | $125,000,000 | Biond Biologics Ltd. (Misgav, Israel) Sanofi entered an exclusive global licensing agreement with Israeli biotech Biond Biologics to develop and commercialize BND-22, an immune checkpoint inhibitor for solid tumors. Terms: $125 million upfront to Biond plus more than $1 billion in potential development, regulatory and sales milestones and tiered double-digit royalties. This is a commercial licensing/partnership that channeled a large upfront payment to an Israeli company. | |
| Partnership | 2021 | — | CytoReason (Tel Aviv, Israel) Sanofi has a multi-year AI drug-discovery collaboration with Tel Aviv-based CytoReason, using its computational immune/disease models. Begun in 2021 (asthma), expanded in January 2023 to license CytoReason's inflammatory-bowel-disease model (undisclosed multimillion-dollar payment), and extended a third time in January 2026 in a deal valued at up to $16 million. Ongoing commercial partnership paying an Israeli company. | |
| Operations in Israel | 2026 | — | State of Israel (commercial presence) Sanofi operates an Israeli subsidiary (Sanofi-Aventis Israel, administrative office in Netanya) and has run clinical trials at Israeli sites; the Netanya administrative office appears as a trial administrative location in Sanofi's ORIGIN trial record. Ordinary commercial and clinical operations, not a donation. |
Frequently asked questions
Did Sanofi S.A. donate money to Israel or Israeli causes?
We have no records of cash donations, but Sanofi S.A. has documented support of other kinds (Partnership, Operations in Israel). See the records on this page.
Where does this information come from?
Every record on this page links to its source — news reports, official company statements, tax filings, or government records. 7 distinct sources are cited for Sanofi S.A.. Our methodology page explains the full verification process.
Sources & citations
Record last updated: 2026-07-21
- PR Newswire (Biond/Sanofi announcement) prnewswire.com
- Times of Israel (Biond/Sanofi) timesofisrael.com
- Goodwin (deal counsel note) goodwinlaw.com
- Times of Israel (Sanofi/CytoReason) timesofisrael.com
- GlobeNewswire (2023 IBD model license) globenewswire.com
- PR Newswire (2026 extension, up to $16M) prnewswire.com
- ClinicalTrials.gov (NCT00069784 — Sanofi-Aventis Administrative Office, Netanya, Israel) clinicaltrials.gov